Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.44 |
| ▸ | MTOR | P42345 | 9/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.44 |
| ▸ | PGK1 | P00558 | 2/20 | 0.40 |
| ▸ | PGK2 | P07205 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314682 | 1.00 | PIK3CA (0.44) | PIK3CAMTORPIK3CGPGK1PGK2 | |
| SCHEMBL2314422 | 0.94 | PIK3CA (0.43) | PIK3CAMTORPIK3CGPGK1PGK2 | |
| SCHEMBL13253978 | 0.87 | PIK3CA (0.44) | PIK3CAMTORPIK3CGPGK1PGK2 | |
| SCHEMBL13253979 | 0.87 | PIK3CA (0.44) | PIK3CAMTORPIK3CGPGK1PGK2 | |
| SCHEMBL2317411 | 0.87 | PIK3CA (0.44) | PIK3CAMTORPIK3CGPGK1PGK2 | |
| SCHEMBL19276304 | 0.84 | PIK3CA (0.38) | PIK3CAMTORPIK3CG | |
| SCHEMBL21017199 | 0.83 | TLR9 (0.38) | PIK3CAMTORPIK3CGPGK1PGK2 | |
| SCHEMBL2314253 | 0.82 | ADORA3 (0.42) | PIK3CAMTORPIK3CGPGK1PGK2 | |
| SCHEMBL2312189 | 0.82 | GBA1 (0.43) | PIK3CAMTORPIK3CGADORA3AHR | |
| SCHEMBL2312181 | 0.82 | GBA1 (0.43) | PIK3CAMTORPIK3CGADORA3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | claimed |
| EP-2350078-B1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | claimed |
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | claimed |
| US-9580426-B2 | Compounds that expand hematopoietic stem cells | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | claimed |
| US-9175266-B2 | Enhancement of natural killer (NK) cell proliferation and activity | GAMIDA CELL LTD. (IL) | 2015-11-03 | — | — | US | claimed |
| US-8927281-B2 | Method for expanding hematopoietic stem cells | IRM LLC (BM) | 2015-01-06 | — | — | US | claimed |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-24 | — | — | US | claimed |
| US-20140023626-A1 | Enhancement of Natural Killer (NK) Cell Proliferation and Activity | GAMIDA CELL INC. | 2014-01-23 | — | — | US | claimed |
| US-20140023623-A1 | Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby | GAMIDA CELL INC. | 2014-01-23 | — | — | US | claimed |
| EP-2350078-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2011-08-03 | — | — | EP | claimed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | claimed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | claimed |
| EP-3524604-B1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3524604-A1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2019-08-14 | — | — | EP | disclosed |
| EP-2788476-B1 | COMPOSITIONS AND METHODS FOR ENHANCED GENERATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS | HUTCHINSON FRED CANCER RES (US) | 2019-05-22 | — | — | EP | disclosed |
| WO-2013086436-A1 | COMPOSITIONS AND METHODS FOR ENHANCED GENERATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2350078-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2011-08-03 | — | — | EP | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | PIK3CA 1299/4885MTOR 1140/4885PIK3CG 1258/4885 |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | PIK3CA 1299/4885MTOR 1140/4885PIK3CG 1258/4885 |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | PIK3CA 1299/4885MTOR 1140/4885PIK3CG 1258/4885 |
| US-20140023626-A1 | Enhancement of Natural Killer (NK) Cell Proliferation and Activity | PBK, IL2, AHR | PIK3CA 4594/4885MTOR 3867/4885PIK3CG 4685/4885 |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | PIK3CA 1299/4885MTOR 1140/4885PIK3CG 1258/4885 |
| US-20140023623-A1 | Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby | AHR, HGF, MTNR1A | PIK3CA 4744/4885MTOR 2700/4885PIK3CG 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.